Universal WorldEvents creates dedicated training role
February 14, 2013Medical Communications, Research and Development, Sales and Marketing Universal WorldEvents
Event management firm Universal WorldEvents has announced the promotion of Sarah Longland to the new role of senior account manager …
NICE rejects Jakavi
February 13, 2013Sales and Marketing Jakavi, NICE
NICE has today issued draft guidance saying it does not recommend Novartis’ Jakavi for patients with myelofibrosis, a rare blood …
Ironwood announces new president of R&D
February 13, 2013Manufacturing and Production, Research and Development, Sales and Marketing Ironwood
Ironwood Pharmaceuticals has announced the promotion of Mark Currie, to senior vice president, chief scientific officer, and president of research …
Sanofi ups stake in Regeneron
February 13, 2013Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap
Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …
Shire pays Impax $48 million
February 12, 2013Sales and Marketing ADHD, Adderall, Impax, Shire
Shire has paid $48 million to settle a long-running legal spat with Impax Laboratories over Shire’s supply of an authorised …
Perrigo buys Rosemont for £180 million
February 12, 2013Manufacturing and Production Perrigo, Rosemont
UK-based Rosemont Pharmaceuticals has been sold by its private equity owner to Perrigo of the US in a £180 million …
Mylan appoints two heads to Board of directors
February 12, 2013Manufacturing and Production, Research and Development, Sales and Marketing Mylan
Mylan has announced the appointment of Melina Higgins, a former partner at Goldman Sachs, and Rajiv Malik, currently Mylan’s president, …
FDA rejects Novo diabetes drugs
February 12, 2013Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba
The FDA has knocked back two of Novo Nordisk’s diabetes drugs – just weeks after they were approved for use …
Merck planning more manufacturing cutbacks?
February 11, 2013Manufacturing and Production Merck, restructuring
Merck & Co has said it intends to make additional reductions to its manufacturing network, although the pace of restructuring …
FDA offers Alzheimer’s guidance
February 11, 2013Research and Development, Sales and Marketing Alzheimer's, FDA, Roche, lilly
The FDA has issued guidance to help companies developing new treatments for patients with early-stage Alzheimer’s disease. The US regulator’s …
Teva plans sale of troubled Irvine plant
February 11, 2013Manufacturing and Production FDA, Teva
Teva has decided to sell off an injectable pharmaceutical production plant in Irvine, California, that was shut down temporarily for …
Teva appoints Arie Belldegrun to Board of directors
February 11, 2013Manufacturing and Production, Research and Development, Sales and Marketing Arie Belldegrun, Teva
Teva Pharmaceuticals has announced that Dr Arie Belldegrun has been appointed by the directors of Teva to fill a vacancy …
£20m research boost for Scottish biotech
February 11, 2013Research and Development, Sales and Marketing Bayer, BioCity Scotland, Dundee, EFPIA
BioCity Scotland and the University of Dundee are to play key roles in a newly-launched pan-European drug discovery project. In …
Novartis’ Nebraska OTC plant still troubles company
February 11, 2013Manufacturing and Production Novartis, OTC
Novartis has been forced to recall various over-the-counter (OTC) medicines made at its plant in Lincoln, Nebraska, after discovering failures …
Contract research news in brief
February 11, 2013Research and Development Antabio, Aptuit, Argenta, Cross Country Healthcare, ICON, PPD, Quintiles, Verum.de
Icon offers $52m for CCH’s clinical services division, plus updates from PPD, Aptuit, Argenta, Quintiles and Verum.de.
Pharma manufacturing news in brief
February 11, 2013Manufacturing and Production Almac, MeadWestvaco, Rexam, UPS, lilly
A round-up of pharma manufacturing news, including facility updates from MeadWestvaco, Rexam, Almac, UPS and Kemwell Biopharma. MeadWestvaco has said …
Sanofi won’t follow trend for spin-offs
February 8, 2013Sales and Marketing Abbott, Pfizer, Sanofi, Viehbacher
Sanofi’s chief executive Chris Viehbacher says the firm plans to maintain its portfolio of business divisions for the foreseeable future, …
‘Challenging’ Europe slows GSK
February 8, 2013Sales and Marketing GSK, austerity, restructuring
‘Challenging’ economic conditions in Europe are among the factors GlaxoSmithKline is blaming for its sluggish performance, with turnover worldwide down …
Lilly abandons RA drug
February 8, 2013Research and Development, Sales and Marketing RA, lilly, tabalumab
Lilly is abandoning its late-stage trial into investigational rheumatoid arthritis (RA) drug tabalumab but insists the move has nothing to …
Lexapro US loss hits Lundbeck
February 7, 2013Sales and Marketing Danish, Lexapro, Lundbeck
The loss of US patent protection on antidepressant Lexapro has put a significant dent in Lundbeck’s financial performance for 2012. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
